MarketInOut Stock Screener Log In | Sign Up
 

AnaptysBio Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 08/07/2026
AnaptysBio Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,632.32 mln
Float19.79 mln
Earnings Date08/10/2026

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

-2.72
Likely reliable

Relative Strength

65 / 100
Outperforming

Debt / Equity

1.07
Elevated leverage

Pre-Tax Margin

18%
Healthy margin

ROE

-1,363
Deeply negative

Business Description

AnaptysBio Inc. is a San Diego-based biotechnology company working to develop treatments for autoimmune and inflammatory conditions. Its pipeline includes several promising drug candidates at various stages of clinical testing, targeting diseases such as rheumatoid arthritis, psoriasis, celiac disease, and certain cancers. The company works alongside partners GSK and Vanda to advance its research programs from early discovery through clinical development.

Key Fundamentals

EPS-1.05
ROE-1,363
RPS8.19
ROIC82.57
ROA-7.42
Interest Cover0.49
EBITDA, mln58.49
EV / EBITDA22.47
EV / EBIT23.45
Revenue, mln232
EV / Revenue5.66

Financial Strength

Altman Z-Score1.79
Piotroski F-Score 5 / 9
Beneish M-Score-2.72
Short Ratio6.75
Short % of Float37.58

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 6.09% 74 / 100   
1 Month -14.99% 13 / 100   
2 Months -13.87% 20 / 100   
6 Months 77.29% 95 / 100   
1 Year 277% 98 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us